Research Opportunities for Medications to Treat Alcohol Dependence: Addressing Stakeholders' Needs

被引:12
|
作者
Litten, Raye Z. [1 ]
Falk, Daniel [1 ]
Ryan, Megan [1 ]
Fertig, Joanne [1 ]
机构
[1] NIAAA, NCIG, Div Treatment & Recovery Res, Bethesda, MD 20892 USA
关键词
Alcohol Medication Development; Alcohol Pharmacotherapy; Research Opportunities; Stakeholders' Needs; UNITED-STATES; ADDICTION; NALTREXONE; PRESCRIPTION; DISORDERS; DRINKING; TRIALS; TRENDS; DRUG;
D O I
10.1111/acer.12193
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
During the past decade, significant advances have been made in the development of medications to treat alcohol dependence. Four medications have been approved by the U.S. Food and Drug Administration for treating alcohol dependencenaltrexone, injectable naltrexone, acamprosate, and disulfiramand several others show promise. The fact remains, however, that because of the heterogeneity of alcohol dependence, these medications will not work for all people, in all circumstances. Moreover, clinicians are not routinely prescribing these medications for alcohol treatment. This commentary poses a number of issues that must be addressed in order to advance the alcohol research field and to make medications a mainstream treatment for problematic drinking. These issues are framed from the perspective of the various stakeholders involved, including clinicians, patients, regulatory agencies, the pharmaceutical industry, and third-party payers. Addressing these issues will not only help to improve treatment but, as further described, will also open up many new research opportunities for alcohol investigators in the coming decade.
引用
收藏
页码:27 / 32
页数:6
相关论文
共 50 条
  • [21] Medications and Micronutrients: Identifying Clinically Relevant Interactions and Addressing Nutritional Needs
    Prescott, Jeffery David
    Drake, Victoria Jayne
    Stevens, Jan Frederik
    JOURNAL OF PHARMACY TECHNOLOGY, 2018, 34 (05) : 216 - 230
  • [22] Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment
    不详
    JOURNAL OF FAMILY PRACTICE, 2017, 66 (10):
  • [23] Qualitative Analysis of Patient Decisional Needs for Medications to Treat Heart Failure
    Turgeon, Ricky D.
    Fernando, Saranee
    Bains, Marc
    Code, Jillianne
    Hawkins, Nathaniel M.
    Koshman, Sheri
    Straatman, Lynn
    Toma, Mustafa
    Virani, Sean A.
    Macdonald, Blair J.
    Snow, M. Elizabeth
    CIRCULATION-HEART FAILURE, 2024, 17 (04) : E011445
  • [24] Delivering on MPTs: addressing the needs, rising to the challenges and making the opportunities
    Malcolm, R. Karl
    Fetherston, Susan M.
    CONTRACEPTION, 2013, 88 (03) : 321 - 325
  • [25] Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development
    Litten, Raye Z.
    Falk, Daniel E.
    Ryan, Megan L.
    Fertig, Joanne B.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2016, 40 (07) : 1368 - 1379
  • [26] Alcohol Tolerance in Human Laboratory Studies for Development of Medications to treat Alcohol Use Disorder
    Haass-Koffler, Carolina L.
    Perciballi, Roberta
    ALCOHOL AND ALCOHOLISM, 2020, 55 (02): : 129 - 135
  • [27] Anti-craving medications for alcohol to treat moderate to severe alcohol use disorder
    Mong, Jon
    Ahamad, Keith
    Bach, Paxton
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2021, 193 (30) : E1196 - E1197
  • [28] Pharmacotherapy for alcohol dependence: Anticraving medications for relapse prevention
    Jung, Young-Chul
    Namkoong, Kee
    YONSEI MEDICAL JOURNAL, 2006, 47 (02) : 167 - 178
  • [29] MEDICATIONS FOR ALCOHOL DEPENDENCE: MECHANISMS, EFFECTIVENESS AND FUTURE DIRECTIONS
    Gowing, Linda
    DRUG AND ALCOHOL REVIEW, 2012, 31 : 17 - 17
  • [30] Medications for alcohol dependence: Rational drug design and DCUK
    Tabakoff, Boris
    Hoffman, Paula
    Vengeliene, Valentina
    Spanagel, Rainer
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2006, 30 (09) : 68A - 68A